IMMIX BIOPHARMA INC.

1,6500

26-ноября-24 16:45:00

15 мин. задержка

Акции

-0,0700

-4,07%

Сегодняшний диапазон

1,6400 - 1,7801

ISIN

N/A

Источник

NASDAQ

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

25 ноя 2024 09:32:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

02 окт 2024 09:32:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

19 сен 2024 09:31:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

28 авг 2024 09:32:00 Источник Nasdaq GlobeNewswire
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

25 июл 2024 21:31:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

08 июл 2024 09:31:00 Источник Nasdaq GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

17 июн 2024 09:35:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

10 май 2024 09:35:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

29 апр 2024 09:39:00 Источник Nasdaq GlobeNewswire
Immix Biopharma on Track to Dose NXC-201 Patients in United States

18 апр 2024 09:32:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 апр 2024 09:36:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

20 мар 2024 09:46:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

05 мар 2024 09:35:00 Источник Nasdaq GlobeNewswire
Immix Biopharma 12 Month Review Progress Update

21 фев 2024 09:31:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

08 фев 2024 16:45:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

07 фев 2024 09:37:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

05 фев 2024 22:30:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces Proposed Public Offering of Common Stock

05 фев 2024 15:20:11 Источник Nasdaq GlobeNewswire
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

24 янв 2024 08:35:00 Источник Nasdaq GlobeNewswire
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

04 янв 2024 09:34:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.